S1204, Viral Screening in Newly Diagnosed Cancer Patients

Recruiting in Palo Alto (17 mi)

+57 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Southwest Oncology Group

No Placebo Group

Trial Summary

What is the purpose of this trial?

The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.

Research Team

Scott D. Ramsey, M.D.

Principal Investigator

Fred Hutchinson Cancer Center

Eligibility Criteria

Inclusion Criteria

presenting for evaluation or treatment of a new cancer malignancy(including hematologic)

confirmed pathologic diagnosis must be within 120 days of registration (Patients presenting for "second opinions" of confirmed malignancies are eligible, including those who have started cancer treatment at other facilities)

at least 18 years of age

Treatment Details

Interventions

• Viral Screening (Screening Test)

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Louisiana Hematology Oncology Associates LLC Baton Rouge, LA

East Jefferson General Hospital Metairie, LA

University Medical Center New Orleans New Orleans, LA

The Don and Sybil Harrington Cancer Center Amarillo, TX

More Trial Locations

Who Is Running the Clinical Trial?

Southwest Oncology Group

Lead Sponsor

Trials

389

Recruited

260,000+

Dr. Lyudmila Bazhenova

Southwest Oncology Group

Chief Medical Officer since 2021

MD from University of California, San Diego

Dr. Richard Schilsky

Southwest Oncology Group

Chief Executive Officer since 2013

MD from University of California, San Diego

SWOG Cancer Research Network

Lead Sponsor

Trials

403

Recruited

267,000+

Dr. Charles D. Blanke

SWOG Cancer Research Network

Chief Executive Officer since 2012

MD from Oregon Health & Science University

Dr. Dawn Hershman

SWOG Cancer Research Network

Chief Medical Officer since 2020

MD from Columbia University

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School